10-Q: Tango Therapeutics Reports Q3 2025 Progress, Strong Cash

Tango Therapeutics announced its Q3 2025 financial results, highlighting positive clinical data for vopimetostat and a strong cash runway into 2028 following a recent $212 million capital raise.

Summary

• Reported net income of $15.9 million for the three months ended September 30, 2025, a significant improvement from a net loss of $29.2 million in the same period of 2024.
• Incurred a net loss of $62.8 million for the nine months ended September 30, 2025, compared to a net loss of $92.6 million for the corresponding period in 2024.
• Collaboration revenue increased to $53.8 million in Q3 2025 from $11.6 million in Q3 2024, primarily due to the truncation of the Gilead collaboration research term and recognition of remaining deferred revenue.
• Research and development expenses decreased to $30.8 million in Q3 2025 from $33.3 million in Q3 2024, mainly due to the discontinuation of the TNG908 and TNG348 clinical programs, partially offset by increased spend on vopimetostat and TNG456.
• Cash, cash equivalents, and marketable securities totaled $152.8 million as of September 30, 2025.
• Successfully completed an underwritten offering and concurrent private placement in October 2025, raising $212.0 million in net proceeds, extending the cash runway into 2028.
• Positive Phase 1/2 clinical trial data for vopimetostat in MTAP-deleted cancers showed an overall response rate (ORR) of 27% and median progression-free survival (mPFS) of 6.4 months across all tumor types.
• Vopimetostat in second-line (2L) MTAP-deleted pancreatic cancer demonstrated an ORR of 25% (n=8) and mPFS of 7.2 months, supporting a planned pivotal trial in 2026.
• Initiated a Phase 1/2 clinical trial for TNG456, a brain-penetrant PRMT5 inhibitor, in May 2025, focusing on glioblastoma (GBM).
• The vopimetostat combination clinical trial with RAS(ON) inhibitors (daraxonrasib and zoldonrasib) began in June 2025, showing early signs of activity and good tolerability.
• TNG260, a CoREST inhibitor, achieved a mPFS of 27 weeks in checkpoint inhibitor resistant STK11 mutant/KRAS wild-type NSCLC patients (n=5), more than double the standard of care PFS of approximately 10 weeks.

Sentiment

Score: 8

Explanation: The company reported a significant improvement in net income for the quarter, driven by collaboration revenue recognition and reduced R&D expenses from program discontinuations. Crucially, positive clinical data for vopimetostat and TNG260, exceeding historical benchmarks in specific indications, coupled with a substantial capital raise extending the cash runway into 2028, indicate strong operational and financial progress. While still incurring overall losses and facing inherent biotech risks, the clinical advancements and strengthened financial position are highly favorable.

Positives

• Achieved net income of $15.9 million in Q3 2025, a significant turnaround from a net loss of $29.2 million in Q3 2024.
• Collaboration revenue surged to $53.8 million in Q3 2025, driven by the full recognition of remaining deferred revenue from the Gilead agreement.
• Successfully raised $212.0 million in net proceeds from an October 2025 capital raise, extending the cash runway into 2028.
• Positive Phase 1/2 clinical data for vopimetostat in MTAP-deleted cancers, demonstrating an ORR of 27% and mPFS of 6.4 months across all tumor types.
• Vopimetostat showed promising results in 2L MTAP-deleted pancreatic cancer, with an ORR of 25% (n=8) and mPFS of 7.2 months, which is more than double historical chemotherapy studies (~10%), supporting a planned pivotal trial in 2026.
• Vopimetostat exhibited a favorable safety and tolerability profile with no drug-related dose discontinuations.
• Initiated a combination clinical trial for vopimetostat with RAS(ON) inhibitors in June 2025, showing early signs of activity and good tolerability.
• Initiated Phase 1/2 clinical trial for TNG456, a brain-penetrant PRMT5 inhibitor, in May 2025, targeting CNS cancers like GBM.
• TNG260 achieved a median progression-free survival (mPFS) of 27 weeks in checkpoint inhibitor resistant STK11 mutant/KRAS wild-type NSCLC patients (n=5), more than double the standard of care PFS of approximately 10 weeks.
• Engaged experienced consultants to support late-stage development and regulatory strategy for the planned pivotal study.

Negatives

• Continued to incur a net loss of $62.8 million for the nine months ended September 30, 2025.
• Discontinued the TNG908 Phase 1/2 clinical trial in November 2024 due to insufficient brain exposure for clinical activity in GBM and portfolio prioritization.
• Discontinued TNG348 (USP1 inhibitor) in May 2024 due to liver toxicity observed in its Phase 1/2 clinical trial.
• Observed no activity for vopimetostat in sarcoma patients (ORR 0%), leading to its exclusion from future development in this indication.
• No evidence of activity for TNG260 in other STK11 mutant cancers beyond STK11 mutant/KRAS wild-type NSCLC.
• Experienced a decrease in interest income due to a lower marketable securities balance.
• Reported a decrease in other income, net, attributed to lower accretion from investments purchased at a discount.

Risks

• Limited operating history and no products approved for commercial sale, with no guarantee of future profitability.
• Faces substantial competition, which may result in others developing or commercializing products more successfully.
• Will need to raise substantial additional funding, and inability to do so on acceptable terms could delay or eliminate product development programs.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies.
• Has never successfully completed any clinical trials, and preclinical programs may never advance to clinical development.
• Focus on novel, rapidly evolving areas of science (genetically defined/biomarker-driven cancers) may not lead to approved or marketable products.
• Reliance on third parties for screening tests, companion diagnostics, and biomarker selection introduces dependencies.
• Clinical product development is a lengthy, expensive process with uncertain outcomes.
• Initial, interim, and top-line clinical data are subject to change and confirmation.
• Results from earlier preclinical studies are not necessarily predictive of later preclinical studies and clinical trials.
• Potential for delays or difficulties in the initiation, enrollment, or dosing of patients in clinical trials.
• Clinical trials may reveal significant adverse events not seen in preclinical studies, impacting regulatory approval or market acceptance.
• Development of product candidates modulating novel pathways may lead to greater R&D expenses, regulatory issues, or unknown adverse effects.
• Delays or inability to obtain required regulatory approvals for product candidates.
• Public health crises may materially and adversely affect business and financial results.
• Reliance on third parties to conduct clinical trials; failure to perform could substantially harm the business.
• Reliance on a limited number of third parties for manufacturing product candidates and active pharmaceutical ingredients (API), including WuXi AppTec as the sole source for clinical-stage API, which is subject to proposed Congressional legislation.
• Inability to obtain new patents, maintain existing patents, and protect intellectual property.
• Risk of infringing third-party patents, potentially leading to damages or inability to manufacture/sell products.
• Development of combination therapies may present more or different challenges than single-agent therapies.
• Inadequate funding for government agencies (e.g., FDA, SEC) could delay approvals or impact business functions.
• Unfavorable global economic conditions, including increased inflation and interest rates, could adversely affect business, financial condition, or results of operations.
• Geopolitical issues, including trade restrictions (tariffs, sanctions) and global conflicts, could disrupt supply chains and operations.
• Healthcare legislative reform measures (e.g., Inflation Reduction Act, Executive Orders on drug pricing) may materially adversely affect pricing, reimbursement, and profitability.
• Comprehensive tax reform legislation, such as the One Big Beautiful Bill (OBBB), could adversely affect business and financial condition, particularly regarding R&D expense capitalization.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities, combined with the $212.0 million net proceeds from the October 2025 capital raise, to fund operating expenses and capital expenditure requirements into 2028. It anticipates continued significant and increasing expenses and operating losses as product candidates advance through preclinical and clinical development. A registrational trial for vopimetostat in second-line pancreatic cancer is planned for 2026, with a safety and efficacy update for the vopimetostat lung cohort also expected in 2026. The ongoing vopimetostat combination study with RAS(ON) inhibitors is believed to have the potential to support a first-line pancreatic cancer pivotal study. Dose optimization for TNG260 in STK11 mutant/KRAS wild-type NSCLC is ongoing. The company will require substantial additional funding to support its growth strategy until significant revenue from product sales is generated.

Management Comments

• Our mission is to discover the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer.
• We believe our approach will provide the ability to deliver deep, durable target inhibition with favorable tolerability and safety profiles, thus potentially maximizing clinical benefit.
• Emerging data from the lung cohort are consistent with expectations, and we anticipate providing a safety and efficacy update in 2026.
• We believe this ongoing clinical trial [vopimetostat + RAS(ON) inhibitors] has the potential to support a first line pancreatic cancer pivotal study in MTAP-deleted/RAS mutated patients.
• Preclinical data for TNG456 showed favorable potency and MTAP selectivity and sufficient brain penetrance to potentially have meaningful efficacy in glioblastoma.
• TNG260 is a first-in-class CoREST inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
• Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.

Industry Context

Tango Therapeutics operates in the highly competitive and rapidly evolving precision oncology sector, focusing on developing novel small molecules for genetically defined or biomarker-driven cancers. Its synthetic lethal targeting approach aims to selectively kill cancer cells while sparing normal cells, addressing a largely unaddressed target space of tumor suppressor gene loss. The company's pipeline, including candidates for pancreatic cancer, lung cancer, and glioblastoma, targets areas of high unmet medical need. The industry is characterized by lengthy and expensive development processes, high attrition rates, and significant regulatory and economic pressures, including potential impacts from healthcare legislative reforms and global supply chain risks, particularly concerning reliance on limited third-party manufacturers like WuXi AppTec.

Comparison to Industry Standards

• Vopimetostat's 25% ORR in 2L MTAP-deleted pancreatic cancer (n=8) is more than double the approximately 10% observed in historical chemotherapy studies.
• TNG260's mPFS of 27 weeks in checkpoint inhibitor resistant STK11 mutant/KRAS wild-type NSCLC (n=5) is more than double the standard of care PFS of approximately 10 weeks.
• The company's cash runway into 2028, following a significant capital raise, positions it favorably compared to many early-stage biotechnology companies that often have shorter funding horizons.
• The synthetic lethal targeting approach is highlighted as unique, aiming to deliver deep, durable target inhibition with favorable tolerability and safety profiles by sparing normal cells, potentially offering an advantage over conventional therapies.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation or legal proceedings as of September 30, 2025.
• No material legal proceedings are currently pending or threatened.

Related Party Transactions

• In August 2025, the company and Sesame Therapeutics, Inc. entered into a use and occupancy sub-lease of office and laboratory space, with total sub-lease payments from Sesame to Tango approximating $0.4 million over a 17-month term, due to common relationships amongst management and board members.
• In October 2025, the company entered into a consulting agreement with Malte Peters, M.D., who also serves on the Tango Board of Directors, for $36,000 per calendar month and an equity grant of 150,000 non-qualified stock options.
• In November 2024, the company and Revolution Medicines, Inc. (RevMed) entered into a Clinical Trial Collaboration and Supply Agreement, which was a related party transaction due to common relationships amongst management and board members at the time of execution.

Stakeholder Impact

• **Shareholders:** Experienced dilution from the recent capital raise, but benefit from an extended cash runway into 2028, providing financial stability. Positive clinical data for vopimetostat and TNG260 could enhance future share value, while program discontinuations represent inherent development risks.
• **Employees:** Continued research and development activities, along with potential for new hires, indicate stable employment and growth opportunities. Stock-based compensation remains a significant component of remuneration.
• **Patients:** Promising clinical data for vopimetostat and TNG260 offer potential new therapeutic options for cancers with high unmet medical needs, such as MTAP-deleted pancreatic cancer and STK11 mutant NSCLC.
• **Suppliers/Creditors:** The strengthened cash position and extended runway reduce credit risk. However, reliance on a limited number of third-party suppliers, particularly WuXi AppTec, introduces supply chain risks, especially given proposed legislative actions.
• **Gilead Sciences:** The truncation of the research term concludes the research portion of the collaboration, but all agreements for future milestones and royalties remain in effect, indicating continued potential for financial benefits from licensed programs.

Next Steps

• Initiate a registrational trial for vopimetostat (TNG462) in second-line pancreatic cancer in 2026.
• Provide a safety and efficacy update from the lung cohort of the ongoing Phase 1/2 clinical trial in vopimetostat in 2026.
• Continue dose optimization for TNG260 in patients with advanced STK11 mutant/KRAS wild type NSCLC.
• Advance the pipeline and use recent capital raise for working capital and general corporate purposes.
• Engage with the U.S. FDA and develop future regulatory strategy with new consultants.
• Continue enrollment in TNG456 Phase 1/2 clinical trial, focusing on GBM.

Key Dates

Recommendation

While the Q3 2025 results show a positive shift to net income and the recent capital raise significantly bolsters the cash position, extending the runway into 2028, the company remains in a high-risk, pre-commercial stage. The positive clinical data for vopimetostat and TNG260 are encouraging and exceed historical benchmarks in specific indications, suggesting potential for future value creation. However, the inherent uncertainties of drug development, including the risk of clinical trial failures, regulatory hurdles, and the need for substantial future funding, warrant a cautious approach. Program discontinuations (TNG908, TNG348) highlight the high attrition rate in biotech. The stock is likely to be volatile based on clinical milestones. For a seasoned investor, holding the stock to observe further clinical trial progression and regulatory milestones for vopimetostat and TNG260, particularly the planned pivotal trial, would be prudent given the current stage of development and the balance of positive and negative factors.

Keywords

Precision Oncology, Clinical Trials, Vopimetostat (TNG462), MTAP-deleted cancer, Pancreatic Cancer, Lung Cancer, TNG456, Glioblastoma (GBM), TNG260, STK11 mutant NSCLC, CoREST inhibitor, HBS1L, FOCAD-deleted tumors, Drug Development, Biotechnology, SEC Filing, 10-Q, Gilead Collaboration, Capital Raise